CytoDyn to Showcase Extended Survival Findings for Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Nov 24 2025

0mins

Source: Globenewswire

Clinical Presentation Announcement: CytoDyn Inc. will present clinical data at the San Antonio Breast Cancer Symposium on December 12, 2025, showcasing sustained remission in patients with metastatic triple-negative breast cancer (mTNBC) following treatment with leronlimab and immune checkpoint inhibitors.
Efficacy of Leronlimab: The company’s research indicates that leronlimab may enhance PD-L1 levels, potentially improving the effectiveness of immune checkpoint inhibitors in mTNBC patients, particularly those with low PD-L1 expression.
Patient Outcomes: The presentation will highlight a group of mTNBC patients treated with leronlimab and PD-L1/PD-1 inhibitors, with some showing long-term remission and no current evidence of disease.
Company Overview: CytoDyn is focused on developing leronlimab, a monoclonal antibody targeting the CCR5 receptor, with applications in oncology and other diseases, emphasizing its commitment to improving patient quality of life through innovative therapies.

Get Free Real-Time Notifications for Any Stock

Monitor tickers like undefined with instant alerts to capture every critical market movement.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.